Sibylle Loibl, MD, PhD, co-chair of the German Breast Group (GBG) and associate professor at the University of Frankfurt, discusses the GeparSepto trial in subgroups of patients with breast cancer.

Patients with HER2-positive disease were treated with pertuzumab (Perjeta) plus trastuzumab (Herceptin) in addition to chemotherapy. Both drugs were given for the entire 24 weeks, and trastuzumab was continued for up to 1 year.

In the HER2-positive population, hormone receptor (HR)-negative patients had a pathological complete response (pCR) rate that was much higher than the other 2 cohorts at 75%. This pCR rate is more important in patients with HER2-positive disease than in patients with triple-negative, says Loibl.

Sibylle Loibl, MD, PhD

Articles

Dr. Loibl Discusses GeparSepto Trial in Breast Cancer